Health Discovery Corporation Files for U.S. and Foreign Patent Protection of New Prostate Cancer Biomarker Discovery.

New Prostate Cancer Biomarker Expression Signature is Highly Accurate in Identifying Prostate Cancer

SAVANNAH, Ga. -- Health Discovery Corporation ("HDC") (OTCBB: HDVY) announced today that it has filed new patent applications in the United States Patent and Trademark Office and in the U.S. Receiving Office for the Patent Cooperation Treaty for U.S. and foreign patent protection for a newly discovered Prostate Cancer Biomarker Expression Signature which is highly accurate for identifying prostate cancer. This new Prostate Cancer Biomarker Expression Signature was demonstrated to have a very high degree of accuracy as demonstrated by an area under the ROC curve of 94%.

"This new and exciting biomarker discovery could play a significant role in a more accurate diagnosis of prostate cancer as well as providing important information for the development of new drug targets for the successful treatment of prostate cancer," commented Dr. Herbert A. Fritsche, Professor of Laboratory Medicine at the University of Texas M.D. Anderson Cancer Center and Chairman of HDC's Science Team. "As medicine becomes increasingly personalized, discoveries of this nature could facilitate the development of new diagnostic tests and innovative treatments for prostate cancer."

Stephen D. Barnhill, M.D., Chairman & CEO of HDC, said, "I firmly believe that this new Prostate Cancer Biomarker Discovery provides a significant opportunity towards providing a more accurate diagnosis of prostate cancer and important new information for identifying new therapeutic targets in treating this potentially devastating type of cancer. This is especially important since The World Health Organization (WHO) estimates that prostate cancer in men is expected to go up 40% worldwide in the next 25 years. HDC is eager to work with both diagnostic and pharmaceutical partners on developing prospective commercial applications for this important new discovery."

In addition, HDC has previously identified and reported additional Expression Signatures of biomarkers that are capable of distinguishing high-grade prostate cancers (Gleason Grade 4 and higher) from less malignant grades. More than 1 million men a year undergo biopsies of the prostate gland after the widely used cancer-screening test reveals moderately elevated levels of prostate specific antigen (PSA) in the blood. Only one in four of these biopsies find evidence of cancer, meaning that around 750,000 of those million plus biopsies were unnecessary. The ability to clearly distinguish between different cancer grades by accurately identifying biomarker expression signatures in tissue, blood, urine or semen, could reduce the number of unneeded biopsies while quickly identifying those men in urgent need of more aggressive treatment.

According to a recent paper published in the Journal of Urology by Dr. Tom Stamey at Stanford University Medical Center, a world-renowned expert on prostate cancer, and a Member of the HDC Science Team "The Era of PSA is over" because of the low accuracy rate of Prostate Specific Antigen in identifying clinically significant prostate cancer. Dr. Stamey believes that a new more accurate test is needed to effectively detect this type of cancer. PSA sales are estimated at over $350 million annually and represent 40% of all annual cancer serum biomarker revenues.

HDC has recently signed licensing agreements with Pfizer (NYSE: PFE), Epigenomics (Frankfurt, Prime Standard: ECX) and Bruker Daltonics (NASDAQ: BRKR).

Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the field of pattern recognition. Through its broad patent portfolio and the efforts of its recognized scientific team, HDC is focused on commercializing its intellectual property in genomic and proteomic biomarker discovery, medical imaging, diagnostics, and pharmaceutical advancements in personalized medicine. The company's patent-protected technology also has significant application in non-medical fields that require manipulation and analysis of large, complex datasets such as insurance, financial markets, Internet search & spam, and homeland security.

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.